Melatonin Study Between Diminished and Normal Responder in IVF
Infertility, Female
About this trial
This is an interventional supportive care trial for Infertility, Female focused on measuring oxidative stress, antioxidants, diminished ovarian reserve
Eligibility Criteria
Inclusion Criteria:
- Infertility patients visiting Bundang CHA hospital between the age of 20 to 40.
- Currently, not being treated for any gynecological or medical diseases.
Exclusion Criteria:
- Current untreated pelvic pathology (moderate-to-severe endometriosis, submucosal uterine fibroids/polyps assessed by the treating specialist to affect fertility, pelvic inflammatory disease,uterine malformations, and hydrosalpinx.)
- Currently enrolled in another interventional clinical trial.
- Concurrent use of other adjuvant therapies (e.g.Chinese herbs, acupuncture).
- Autoimmune disorders.
- Undergoing preimplantation genetic diagnosis.
- Concurrent use of any of the following medications (Fluvoxamine,Cimetidine, Quinolones, Carbamazepine, rifampicin,Zolpidem, zopiclone, and other non-benzodiazepine hypnotic, other CYP1A2 inducers.
- Genetic disorders regarding galactose intolerance, lactase deficiency, glucose-galactose malabsorption
- Inability to comply with trial protocol.
Sites / Locations
- Bundang CHA medical center
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
melatonin administration group
placebo comparator
Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period. For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval.
Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period. For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval.